Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Rhea-AI Summary
Zentalis Pharmaceuticals (NASDAQ: ZNTL) will present two scientific posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. One poster reports preclinical data on azenosertib combination strategies for Triple-Negative Breast Cancer; the other reports real-world Cyclin E1 biomarker findings in ovarian cancer.
Poster details include presentation dates, times, abstract numbers, and presenters; posters will be posted on the company Supporting Publications page when presented.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, ZNTL was flat while scanner peers were mixed: BMEA up 4.10%, FATE up 6.17%, and EQ down 1.16%. Broader biotech moves do not clearly track this AACR-focused headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Investor conferences | Neutral | +1.7% | Announcement of participation in three upcoming investor conferences and webcasts. |
| Feb 03 | Investor conference | Neutral | -9.6% | Notice of fireside discussion at Guggenheim biotech summit with webcast access. |
| Jan 06 | Corporate update | Positive | +29.9% | Detailed 2026 milestones for azenosertib and disclosure of cash runway into late 2027. |
| Nov 10 | Earnings and pipeline | Positive | +6.1% | Q3 2025 results, cash position, lower operating expenses, and trial timelines reported. |
| Nov 03 | Inducement grant | Neutral | -8.3% | Stock option inducement grant to a new employee under 2022 Inducement Plan. |
News tied to azenosertib program and financial updates has often coincided with positive next-day moves, while routine corporate actions show mixed reactions.
Over the past months, Zentalis has consistently highlighted progress for azenosertib in Cyclin E1‑positive platinum‑resistant ovarian cancer. A Jan 6, 2026 corporate update and a Nov 10, 2025 earnings release both emphasized azenosertib trial milestones and cash runway into late 2027, and were followed by positive price reactions. Conference participation headlines in February 2026 produced mixed, generally modest moves. Today’s AACR poster news extends the azenosertib narrative into Triple‑Negative Breast Cancer and real‑world ovarian cancer data.
Market Pulse Summary
This announcement highlights two AACR 2026 posters that broaden the azenosertib story into Triple‑Negative Breast Cancer and deepen understanding of Cyclin E1‑positive ovarian cancer using real‑world data. It reinforces the company’s biomarker‑driven strategy without adding new clinical efficacy or safety readouts. In context of earlier disclosures about cash runway and pivotal trial planning, investors may focus on how these data inform future trial design, patient selection, and the competitive positioning of azenosertib.
Key Terms
antibody drug conjugates medical
adc medical
triple-negative breast cancer medical
cyclin e1 medical
biomarker medical
wee1 inhibitor medical
platinum-resistant ovarian cancer medical
real world data medical
AI-generated analysis. Not financial advice.
| Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer |
| Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data |
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA.
“We are excited to highlight the potential to expand the opportunity for azenosertib as a combination therapy with cytotoxic agents, including antibody drug conjugates (ADC) and chemotherapy, for Triple-Negative Breast Cancer, a subtype of breast cancer with elevated Cyclin E1 expression. These data support clinical study of azenosertib in tumor types beyond ovarian cancer,” said Julie Eastland, Chief Executive Officer. “In addition, the Cyclin E1 biomarker findings in ovarian cancer based on real world data reinforce the high unmet need for this biomarker-selected patient population with poor prognosis. Our biomarker-driven strategy for azenosertib monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer has potential to address this unmet need.”
AACR poster presentation details are below:
Title: “WEE1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer: Evaluating Single Agent and Combination Activity of Azenosertib in Preclinical Models”
Abstract Number: 2012
Date/Time: Monday, April 20, 2026, 2:00 p.m. - 5:00 p.m. PDT
Presenting Author: Alexandra Levy, MS
Title: “Real-World Treatment Patterns and Outcomes Reveal Distinct Clinical Trajectories of Patients with Cyclin E1-Positive Ovarian Cancer”
Abstract Number: 1708
Date/Time: Sunday, April 19, 2026, 2:00 p.m. - 5:00 p.m. PDT
Presenting Author: Jinkil Jeong, PhD
The posters can be accessed on the Supporting Publications page of the Zentalis website at the time of each presentation’s session.
About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.
Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential for azenosertib to be first-in-class; the potential benefits of azenosertib, including the potential for azenosertib to be an important treatment option for patients with ovarian cancer, triple negative breast cancer or other indications; the broad franchise potential of azenosertib; the Company’s biomarker-driven strategy for azenosertib; and our participation in poster presentations. The terms “anticipate,” “advance,” “believe,” “design,” “develop,” “expect,” “intent,” “look forward,” “on track,” “plan,” “position,” “potential,” “runway,” “strategy,” “target,” “upcoming,” and “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
FAQ
What will ZNTL present at AACR 2026 and when are the sessions?
What is the focus of Zentalis's April 20, 2026 poster (Abstract 2012)?
What does ZNTL’s April 19, 2026 poster (Abstract 1708) report about Cyclin E1 in ovarian cancer?
Who are the presenting authors for Zentalis’s AACR 2026 posters?
Where can investors access Zentalis’s AACR 2026 posters after presentation?
How do these AACR posters relate to ZNTL’s clinical strategy for azenosertib?
